PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2006
CASE
AUTH/1833/5/06 Allen

AUTH/1833/5/06: AstraZeneca v GlaxoSmithKline β€” CONCEPT study leavepiece found misleading for missing dosing context

AstraZeneca challenged a GSK leavepiece on the CONCEPT asthma study. The Panel ruled it misleading for omitting key context on average doses…

2006
CASE
AUTH/1789/1/06 AstraZeneca

AstraZeneca β€˜Happy Birthday’ Arimidex mailing envelope ruled disguised promotion (AUTH/1789/1/06)

An Arimidex mailing used an envelope printed β€œHappy Birthday” with candles and no company identifiers. The PMCPA ruled it gave a misleading…

2007
CASE
AUTH/2023/7/07 Pfizer ⭐ Case of the Week

Pfizer: Champix GP referral tear-off pad seen by patients promoted a POM and undermined GP prescribing (AUTH/2023/7/07)

A Champix GP referral letter pad used by smoking cessation advisers/pharmacists was handed to patients to take to GPs. PMCPA found exaggerated…

2006
CASE
AUTH/1802/2/06 Merck

Merck breached ABPI Code over β€˜More GI-friendly’ Glucophage SR ad and illegible prescribing information (AUTH/1802/2/06)

A PCT medicines management lead challenged a Glucophage SR journal ad. PMCPA ruled the β€˜More GI-friendly than IR metformin!’ headline was misleading/unsubstantiated…

2006
CASE
AUTH/1806/3/06 GlaxoSmithKline

GSK nurse advisor audit services criticised in The Sunday Times: PMCPA found no breach (AUTH/1806/3/06 & AUTH/1809/3/06)

Media and GP complaints alleged GSK-sponsored nurse audits and bonuses were designed to influence prescribing. PMCPA found the services enhanced patient care,…

2006
CASE
AUTH/1858/6/06 Pfizer

Pharmacist v Pfizer: Times statins article and β€˜bad medicine’ quote (AUTH/1858/6/06) – No breach

A pharmacist challenged Pfizer quotes in a Times article about switching to generic statins. The Panel assessed Pfizer’s briefing to the journalist…

2015
CASE
Shield Therapeutics

Shield: Feraccru HCP website FAQ on pregnancy/breastfeeding omitted key SPC precaution (breach Clauses 3.2, 7.2, 9.1)

Feraccru HCP website FAQs were challenged. Hb/CKD wording was not a breach, but pregnancy/breastfeeding FAQ omitted the SPC precaution to avoid use,…

2011
CASE
AUTH/2401/4/11 Meda ⭐ Case of the Week

AUTH/2401/4/11: Anonymous v Meda – Promotion of Rhinolast (No breach; outwith scope)

PMCPA case AUTH/2401/4/11 (Anonymous v Meda) about promotion of Rhinolast. The matter was ruled outwith the scope of the ABPI Code; no…

2018
CASE
AUTH/3029/4/18 GW Pharmaceuticals

GW Pharmaceuticals: meeting hospitality and pre-licence Epidiolex slide deck allegations (AUTH/3029/4/18) – No breach

Complaint alleged inappropriate lunch hospitality and pre-licence promotion/uncertified slides for unlicensed Epidiolex. Panel found complainant hadn’t proved breaches; unsolicited request exemption applied.…

2018
CASE
AUTH/3106/10/18 Janssen

Janssen voluntary admission: Zytiga ad ran twice with out-of-date prescribing information (AUTH/3106/10/18)

Janssen admitted a Zytiga journal ad ran in Sept and Oct 2018 with superseded prescribing information. Despite third-party errors, the PMCPA held…

2016
CASE
AUTH/2900/11/16 Sanofi

Sanofi: Clinical trial disclosure (Lyxumia) and (Zaltrap) β€” AUTH/2900/11/16 & AUTH/2910/11/16

PMCPA Director complaint about clinical trial disclosure for Lyxumia and Zaltrap. Outcome: No breach and deemed outwith the scope of the Code…

2019
CASE
Shionogi

Shionogi Europe: LinkedIn posts about Fetcroja ruled pre-licence promotion and public promotion of a POM

Two Shionogi Europe LinkedIn posts celebrating Fetcroja’s CHMP update and marketing authorisation were ruled pre-licence promotion and, once authorised, promotion of a…

2019
CASE
AUTH/3288/12/19 Biogen ⭐ Case of the Week

AUTH/3288/12/19: NHS Worker v Biogen β€” alleged promotion by an MSL at a social event (No breach)

Anonymous NHS worker alleged a Biogen MSL promoted Tysabri to an MS patient at a wedding. Panel found the complaint unproven on…

2019
CASE
Novartis Pharmaceuticals UK

Novartis breached ABPI Code over Kisqali leaflet: unclear combination partner and outdated survival-data footnote

A Kisqali leaflet used at a breast cancer meeting was ruled misleading for not clearly limiting OS claims to the AI combination…

2020
CASE
AUTH/3293/1/20 Boehringer Ingelheim

Boehringer Ingelheim breached ABPI Code over Pradaxa 110mg website claim implying use in β€œany patient at increased risk of bleeding” (AUTH/3293/1/20)

PMCPA found a Pradaxa 110mg landing page claim (β€œrecommended for use in any patient at increased risk of bleeding”) misleading because Pradaxa…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training